Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2022

View Archived Issues

ADAM10 may be a promising therapeutic target for AML

Sunshine Lake Pharma patents new GCGR and/or GLP-1 receptor agonists

Eubulus Biotherapeutics discloses new GPX4 inhibitors

Roche presents new EGFR mutant inhibitors

Reistone Biopharma divulges new CatC inhibitors

Palacky University patents new terpenoid derivatives

Novel mouse models of BrafV600E-driven thyroid tumors

Alaunos and NCI extend CRADA to assess use of Sleeping Beauty technology for TCR T-cell therapy

Ascentage receives IND clearance for first-in-human study of EED inhibitor APG-5918

HNSCC treatment should focus on targeting TSPAN1

Generian and Mitobridge collaborate to discover and develop small molecules for undruggable targets

Tumors might be nudged to more treatable state

IAMA reports responses with selective NKCC1 inhibitors in animal models of Down syndrome and autism

Anti-VISTA monoclonal antibody KVA-12.1 produces antitumor responses in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...